The prescription-free test you can take at home will help discern which respiratory virus you have, as symptoms often overlap ...

(NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the ...

“Samples were sparse, the TV ads were late, and they were too benign and not exciting.” Rubin also believes Pfizer did not chase the right market. “They did not court the nurses, the ...

On Sunday, The Guardian issued an article that spoke of a UK study that could transform how cancer is treated. The ...

Pfizer is a global pharmaceutical giant with an impressive portfolio of over 350 marketed medicines, 113 experimental candidates in clinical trials, and a presence in more than 200 countries.

Looking at Pfizer's recent performance in business turnaround, I think the recovery in PFE stock should continue in the medium term - the 10% total return since June 2024 may be just the beginning ...

Pfizer has announced the withdrawal of all lots of OXBRYTA approved for treating sickle cell disease (SCD) from worldwide ...

Sept. 14 (UPI) --A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical tests, drugmaker Pfizer announced Saturday. The ...

Pfizer will receive around 2.66 billion pounds ($3.56 billion) in aggregate from Haleon from an offering and a share buyback. Goldman Sachs International said Tuesday that the pharmaceutical ...

Pfizer (PFE) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of ...

Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. Pfizer’s oncology chief has warned that the Biden administration’s drug price reforms could hurt ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time ...